Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing Weekly

Review of hedge fund launches, closures, trends, regulatory and legal events - week 35

Saturday, September 04, 2010

Kirsten Bischoff, Opalesque New York:

With the end of summer holidays fast approaching the news of launches was scarce, but last week, we learned about the following new fund launches from Collard Capital (Global Macro fund), a group of ex-Mizuho traders (Japan equity), an absolute return fund from Hasley Investment Management, and Galtere (agriculture PE). UCITS continue to roll out with Signet announcing a global fund of UCITS, and Swiss private bank Clariden Leu’s launch of a fund of UCITS, in partnership with Olympia Capital. Also launching will be a new fund of funds based in Sweden (Merrant Select), the first officially registered hedge fund in China from E Fund Management and Majedie Investments in London announced the launch of Javelin Capital, a subsidiary asset management business.

Index results released for August included: Credit Suisse's Liquid Alternative Beta Index -1.14%, 1.81% YTD

Hedge fund assets continue to be slowly chipped away by redeeming investors and performance that has lagged the markets. The result is a lack of inflows that has left industry assets at the lowest levels since November 2009. Funds that are seeing assets are fixed income strategies with investors flocking to the positive returns (only one negative month in the past 19 according to Trim Tabs/Barclayhedge), and absolute return funds, which rose $7bn this year, even on flat returns. Harcourt saw its own aum rise to 4.7bn in 2010 and the Reyl Group is the latest manager to declare the time is ripe for hedge fund seeding.

Hedge funds performance information for August began to trickle out as the week progressed and we learned that out of the larger firms Greenlight gained 4% in August, Och Ziff eked out ......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for